Prompt Lispro Fin appears on two pages that describe meaningfully different services. One presents an account for placing trades; the other emphasizes reviewing information before making an investment decision. We have not established that the two domains share a company or product.
A cited page is a source of claims, not independent verification.
The offers we found
The account presentation at modelexorex-100.com, captured on 21 September 2026, advertises AI-assisted investing and funding from INR21,000. Its sequence runs from registration through funding to trading, with buy, hold and watch prompts. These are advertised functions, not a platform we operated.
The about page at modelexorex100.net instead emphasizes data analysis, decision support and performance records that users can inspect. It says it is not providing personalized financial advice. That description does not establish execution, custody or access to the account described on the other domain.
Why the difference matters
Someone paying for analytical information is making a different purchase from someone funding an account that can place orders. The same brand text does not settle who receives the money, where assets are held or who handles a withdrawal. We cannot treat the INR figure as a price for both sites.
Our view
The useful feature of these pages is that their stated roles can be compared directly. Their limitation is the missing authenticated relationship between those roles and a contracting company. Before proceeding, request the agreement for the specific domain and ask whether the service supplies information, executes instructions or introduces another provider. Costs, account results and permissions remain unverified; there is no tested performance score in this review.